What this page establishes
- Fatigue is a reported adverse reaction in semaglutide weight-management labelling, alongside the dominant GI reactions.
- GI adverse events cluster during dose escalation and are generally mild to moderate, which is when energy complaints are also most reported.
- Cardiorespiratory fitness did not improve with GLP-1 treatment alone in randomised data; only the exercising arms improved VO2peak relative to fat-free mass.
- Semaglutide injectable: 0.25 / 0.5 / 1.0 / 1.7 / 2.4 mg weekly, 4 weeks per step, 2.4 mg maintenance; 14.9% mean loss at 68 weeks (STEP 1).
Quick answers
Can I just eat more to fix it?
The direct answer is to shrink the deficit, and capacity is why that is hard. If the pattern is specifically gym performance, carbohydrate is what has usually fallen furthest and it is the cheapest part of intake to add back.
Read the full answer
How fast the weight is coming off is the bigger lever, and that one belongs to your prescriber.Does feeling weak in the gym mean I'm losing muscle?
Not on its own. Muscle glycogen changes over days and shows up straight away as reduced capacity for hard efforts, while lean tissue changes over months.
Read the full answer
Lean loss is real on this class, around 40% of weight lost in the STEP 1 DXA substudy and about 26% in SURMOUNT-1, in trials with no resistance training attached. A bad session this week is still far more likely to be fuel.Is caffeine a reasonable way to push through it?
It masks the sensation without touching the cause, and the causes here are findable ones. Fatigue that persists at a stable dose is the case for looking rather than propping up.
Read the full answer
Caffeine on this class has its own page at GLP-1 and caffeine.
Fatigue is a reported adverse reaction in semaglutide weight-management labelling, so feeling flat is not something you invented. It is also rarely a dead end. In most cases the tiredness traces to something you can identify: the energy deficit itself, carbohydrate intake falling further than total calories, dehydration, low iron or B12 after months of smaller portions, or glucose running lower than your body has adapted to. Fatigue during dose-escalation weeks is a different question from fatigue that persists at a stable dose. The second one is worth investigating.
How common fatigue actually is in the trials
Fatigue appears in semaglutide weight-management labelling alongside the dominant GI reactions, which are the headline tolerability issue on this class. Nausea affected about 44% of semaglutide 2.4 mg participants in STEP 1 against 16% on placebo, and tirzepatide figures in SURMOUNT-1 ran 31 to 43% depending on dose.
Those GI events cluster during dose escalation and are generally mild to moderate. Energy complaints follow much the same curve in reports, which is one reason to date your fatigue against your titration schedule before drawing conclusions.
The energy-deficit explanation and why it is rate-dependent
Fewer calories in means less substrate available, and the body responds by reducing spontaneous movement and thermogenesis. That is not a drug effect. It is what happens in any sizeable deficit, and this class produces deficits people have rarely sustained voluntarily.
The size of the deficit tracks with how quickly weight is coming off. Someone losing 1% of body weight a week is running a much larger gap than someone losing 0.5%, and the fatigue tends to follow. Rate of loss is a titration question, which makes it a prescriber conversation rather than something to adjust yourself.
Glycogen, carbohydrate intake and gym performance specifically
There is a distinctive pattern worth recognising: fine at work, flat in the gym. That usually points at glycogen rather than at anything systemic.
Protein and fat tend to get prioritised when appetite is low, and carbohydrate is what quietly disappears. Muscle glycogen is the substrate for high-intensity work, so depletion shows up first as reduced capacity for hard efforts rather than as general tiredness. Aerobic capacity has its own finding here: cardiorespiratory fitness did not improve with GLP-1 treatment alone in randomised data, and only the exercising arms improved VO2peak relative to fat-free mass. The drug does not make you fitter. Training does.
Micronutrients when portions shrink
Smaller total food volume reduces intake of iron, B12 and other micronutrients over months, and deficiency there produces genuine fatigue that no amount of rest fixes. This is a slow problem, so it tends to appear well after the initial adjustment period, which makes people less likely to connect it to eating less.
Iron, B12 and vitamin D are the routine bloods clinicians commonly check when fatigue persists past a few months on reduced intake. Whether that is warranted for you is your clinician's determination, not a self-ordered panel.
Dehydration as a fatigue driver
Fluid intake drops on this class without anyone deciding to drink less, because a large share of daily water comes from food. Fatigue and mild volume depletion travel together, and this is the cheapest thing on the list to check.
It also connects to the labelled harm pathway. FDA labelling warns of serious kidney injury resulting from dehydration, mostly following nausea, vomiting or diarrhoea. Fatigue with reduced urine output is a different conversation from fatigue alone.
Glucose control changes in people with diabetes
Someone whose glucose has run high for years can feel flat when it comes down into range, even though the readings are better. That adaptation takes weeks.
The other possibility is actual hypoglycaemia from an unadjusted regimen. ADA Standards of Care 2026 instruct that when a GLP-1 receptor agonist or dual agonist is added, sulfonylureas be discontinued or reduced and insulin adjusted, with bolus reduced 10 to 20% and basal about 10% if HbA1c is under 7.5%. If those adjustments have not happened, fatigue may be the mildest symptom you get.
Strength is not guaranteed to fall
Lean soft tissue accounted for roughly 40% of weight lost in the STEP 1 DXA substudy and about 26% in SURMOUNT-1, with a network meta-analysis putting the class average near 25%. None of those trials included a structured resistance-training programme.
Against that, handgrip strength rose by 4.5 kg at 12 months in the SEMALEAN cohort, so strength decline is not a universal outcome. That is observational and single-cohort, so treat it as encouraging rather than settled.
When to contact a clinician
Persistent fatigue at a stable dose deserves investigation rather than acceptance. Some of these need it sooner than others.
- Fatigue with breathlessness, chest pain or palpitations. The labelling on this class already instructs reporting palpitations.
- Fainting or near-fainting.
- Fatigue alongside persistent vomiting or reduced urine output, which is the labelled dehydration pathway.
- Profound weakness, or new difficulty with stairs, which is a different problem from tiredness.
- Low mood alongside the fatigue, which warrants its own conversation.
The evidence, one row per claim
| Claim | Tier | Source |
|---|---|---|
| Fatigue is a reported adverse reaction in semaglutide weight-management labelling, alongside the dominant GI reactions. | established | WEGOVY US Prescribing Information, FDA |
| GI adverse events cluster during dose escalation and are generally mild to moderate, which is when energy complaints are also most reported. | established | Rubino et al., GI tolerability in SURMOUNT-1 to -4 |
| Cardiorespiratory fitness did not improve with GLP-1 treatment alone in randomised data; only the exercising arms improved VO2peak relative to fat-free mass. | established | Physical Fitness with Exercise and GLP-1 RA Treatment (Sports Medicine) |
| Handgrip strength rose by 4.5 kg at 12 months in the SEMALEAN cohort, so strength decline is not a universal outcome. | emerging | SEMALEAN study |
| Specific claims that GLP-1s cause mitochondrial dysfunction or 'metabolic shutdown' are not supported by trial evidence. | anecdotal | unsourced |
| Semaglutide injectable: 0.25 / 0.5 / 1.0 / 1.7 / 2.4 mg weekly, 4 weeks per step, 2.4 mg maintenance; 14.9% mean loss at 68 weeks (STEP 1). | established | STEP 1 |
| Tirzepatide: 2.5 mg initiation then 5 / 10 / 15 mg weekly maintenance; 16.0% / (10 mg intermediate) / 22.5% mean loss at 72 weeks (SURMOUNT-1). | established | Eli Lilly / NEJM |
Questions people ask
Is being tired on its own a reason to come off?
Most of the candidates get checked first: the size of the deficit, carbohydrate intake, hydration, and iron or B12 after months of smaller portions. The lever short of stopping is a slower rate of loss, which is a titration conversation rather than a decision to make alone.
Sources
- WEGOVY US Prescribing Information, FDA
- Rubino et al., GI tolerability in SURMOUNT-1 to -4
- Physical Fitness with Exercise and GLP-1 RA Treatment (Sports Medicine)
- SEMALEAN study
- STEP 1
- Eli Lilly / NEJM
Keep reading
- GLP-1 and Working Out: Strength Training, Muscle Loss and ProteinLean mass loss is real and measured. The trials that measured it mostly had nobody lifting, so treat those num
- GLP-1 and Hydration: Why Fluid Intake Drops and Why It MattersA soft wellness topic with a hard regulatory warning behind it: dehydration following GI symptoms is the docum
- GLP-1 and Protein: How Much, and Why It Is Hard to EatThe protein evidence predates GLP-1s and is solid. The new problem is not the target, it is reaching one when
- GLP-1 and Fasted TrainingAlmost everyone on this drug trains closer to fasted by default. The question that matters is whether total da
- GLP-1 and Mental Health: Mood, Anxiety and What the Data ShowThe label's own monitoring instruction is the operative fact. Reward-circuit involvement is real. Attribution